Gary Middleton
University Hospitals Birmingham NHS Foundation Trust · 460 works · 30,309 citations · h-index 69
Top works
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
- Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- Lung adenocarcinoma promotion by air pollutants
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
- Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study